Amarin's Poland launch tests Vazkepa's value with private payers while revenue falls 20%

What happened

Amarin reported a slim third-quarter 2026 net profit, a return to profit, even though revenue fell 20%. The company's results release does not, in the summary available to us, explain the drivers of the decline or give the comparison period, so the cause of the fall is not yet known from our records.

The more interesting commercial detail is in Poland. Amarin's partner Recordati has started selling icosapent ethyl, marketed as Vazkepa, without public reimbursement. Patients or other private payers therefore carry the cost. Pricing, expected volumes and any plans to seek reimbursement are not in the records.

Why a privately paid launch matters

Launching without reimbursement is a deliberate trade-off. A product can reach patients and prescribers sooner, and a company can build real-world experience while it works through national pricing and reimbursement procedures. The risk is that uptake stays limited when patients must fund treatment themselves, especially for a therapy intended for long-term use.

For Amarin the move sits alongside a shrinking top line. A thin profit after a 20% revenue fall suggests the company is under pressure to find incremental sales. Whether a private-pay market in Poland can contribute meaningfully is not yet known. Nothing in the records gives sales figures for the Polish launch, so any view on its scale would be speculation.

For other manufacturers, the case illustrates a practical question that pricing teams face in markets where reimbursement is slow or uncertain. Is a self-pay launch a useful bridge, or does it set a visible list price that later complicates negotiations with the payer? The records do not say how Recordati has approached this.

Contrast: other access pathways in this week's records

Other items from the same day show how differently access can be structured. In the US, Replimune says its oncolytic HSV-1 therapy Tudriqev, given with nivolumab for advanced melanoma, became commercially available in early October after accelerated approval. NCCN listing and payer policies are emerging, while the confirmatory Phase 3 trial is still enrolling. There, the access question is about coverage policy and guideline support for a product whose evidence base is still being completed.

In Italy, AIFA has updated the Monitoring Registry for Fabhalta (iptacopan) in C3 glomerulopathy. AIFA uses such registries to manage prescribing and reimbursement for selected products. The notice does not describe what changed, so prescribers and hospital pharmacies need to check the revised version themselves.

Taken together, the three cases show three models: private payment ahead of reimbursement in Poland, payer-policy build-out under accelerated approval in the US, and registry-controlled reimbursed access in Italy. Each puts different demands on evidence generation, data collection and contracting.

Who is affected

Teams most affected are those with products in cardiovascular or other chronic-use categories, where a private-pay launch would depend on patients' willingness to pay over time. Polish payers and HTA bodies will also be affected, since a product already on the market privately can shift the conversation about unmet need and budget impact. How they will respond is not stated in the records.

Supply continuity is a related access factor. The Danish Medicines Agency (DKMA) posted updates on supply problems for Rimactan 300 mg (rifampicin) capsules from two suppliers, 2care4 ApS and Sandoz A/S, though the records give no cause or duration. DKMA also withdrew an earlier shortage concern for Rapamune (sirolimus) oral solution from Pfizer ApS. These are small, unconnected items, but they are a reminder that reimbursement and price do not guarantee access if product is not available.

What to watch

The first signal will be Amarin's own commentary on the Polish launch: any disclosed uptake, price or timeline for a reimbursement application. Also watch whether Recordati extends the non-reimbursed approach to other markets, though no such plan appears in the records.

Beyond Amarin, the question is whether self-pay launches become a more common bridge strategy where reimbursement timelines are long. For now, one product in one country is not a trend. The more useful step is to compare what each access model requires in evidence, data and contracting, and to plan for the costs and risks of whichever route a launch takes.